文献速递妇科

卵巢癌中MELK表达与不良预后相关,OTSSP167抑制MELK可阻断卵巢癌细胞增殖和活力

MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells.
PubMed 文献 · Gynecol Oncol · 2017-02-14

该研究通过生物信息学分析9个卵巢癌转录组数据集共1241例患者,发现MELK高表达与组织学分级和不良无进展生存相关;在细胞系中敲低或抑制MELK可导致G2/M期阻滞和凋亡,OTSSP167在顺铂和紫杉醇耐药细胞中仍保留细胞毒性。

要点

  • MELK高表达与卵巢癌组织学分级相关(n=6个数据集,p<0.05)。
  • MELK高表达与卵巢癌无进展生存期相关(HR 5.73,p<0.01)。
  • OTSSP167抑制MELK可诱导G2/M期阻滞和凋亡,在顺铂和紫杉醇耐药细胞中保留细胞毒性。

核心结论

  • OTSSP167抑制MELK可能成为治疗侵袭性、进展性和复发性卵巢癌患者的策略。

研究设计与样本

  • 对9个卵巢癌转录组数据集共1241例患者进行生物信息学分析。
  • 在卵巢癌细胞系中通过shRNA敲低或OTSSP167抑制MELK,采用集落形成和MTT(增殖)实验、Western blotting(凋亡)和流式细胞术(细胞周期分析)进行评估。

主要发现

  • MELK表达升高与卵巢癌患者组织学分级相关(n=6个数据集,p<0.05)。
  • MELK表达升高与卵巢癌患者无进展生存期相关(HR 5.73,p<0.01)。
  • 其他癌症中MELK表达升高与无病生存期相关(n=3495,HR 1.071,p<0.001)。
  • 抑制或敲低MELK通过G2/M期细胞周期阻滞减少多种卵巢癌细胞系的增殖及锚定依赖性和非锚定依赖性生长,最终导致凋亡。
  • OTSSP167在顺铂和紫杉醇耐药的IGROV1和TYK-nu卵巢癌细胞中保留细胞毒性,并使OVCAR8细胞对卡铂敏感但对紫杉醇不敏感。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Maternal embryonic leucine-zipper kinase (MELK) shows oncogenic properties in basal-like breast cancer, a cancer subtype sharing common molecular features with high-grade serous ovarian cancer. We examined the potential of MELK as a molecular and pharmacological target for treatment of epithelial ovarian cancer (EOC). METHODS/MATERIALS: Bioinformatic analysis was performed on nine OC transcriptomic data sets totaling 1241 patients. Effects of MELK depletion by shRNA or inhibition by OTSSP167 in cell lines were assessed by colony formation and MTT (proliferation) assays, Western blotting (apoptosis), and flow cytometry (cell cycle analysis). RESULTS: Elevated MELK expression was correlated with histological grading (n=6 data sets, p<0.05) and progression-free survival (HR 5.73, p<0.01) in OC patients and elevated MELK expression in other cancers with disease-free survival (n=3495, HR 1.071, p<0.001). Inhibition or depletion of MELK reduced cell proliferation and anchorage-dependent and -independent growth in various OC cell lines through a G2/M cell cycle arrest, eventually resulting in apoptosis. OTSSP167 retained its cytotoxicity in Cisplatin- and Paclitaxel-resistant IGROV1 and TYK-nu OC cells and sensitized OVCAR8 cells to Carboplatin but not Paclitaxel. CONCLUSION: MELK inhibition by OTSSP167 may thus present a strategy to treat patients with aggressive, progressive, and recurrent ovarian cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Kohler RS, Kettelhack H, Knipprath-Mészaros AM, et al. MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells. Gynecol Oncol. 2017. PMID: 28214016. doi:10.1016/j.ygyno.2017.02.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。